Considering the fact that β-hCG is an immune suppressor and is overexpressed in BRCA1 defective cancer cells, inhibiting β-hCG could be a better treatment strategy with immense clinical application than using immune modulators for reducing the growth of such cancers. Here, BRCA1 is linked to cancer.